May 5 2015
Garvan Institute of Medical Research, one of Australia’s leading biomedical research institutes, announced today they have selected the BiOptix 404pi for their drug discovery research.
BiOptix is a life science tools company that provides an affordable and powerful solution for drug discovery scientists that require label-free, real-time detection of biomolecular interactions. The BiOptix 404pi is used for early-stage drug development, allowing scientists to measure kinetics, affinity constants and concentration. The instrument will be used in the Solvanix labs at the Garvan Institute of Medical Research in Sydney, Australia for stability engineering of human antibody reagents for therapeutic purposes.
“After investigating other SPR instrumentation, we believe that the BiOptix 404pi is the best instrument to aid in our research because of its reliability, high sensitivity and ease of use,” said Daniel Christ, Ph.D., an Associate Professor of Medicine at New South Wales University and Head of the Antibody Therapeutics Lab at the Garvan Institute of Medical Research. “The flexibility of the BiOptix instrument will allow us to use it for a myriad of biomolecular tests, focusing on immunology.”
The Garvan Institute of Medical Research is pioneering study into many of the most widespread diseases including cancer, neurodegenerative and mental diseases, disorders of the immune system, diabetes and obesity, osteoporosis and other skeletal disorders. Solvanix, a company with a technology for improving stability and reducing the aggregation of fully human antibodies, will also utilize the BiOptix 404pi in their research.
“We are pleased to add Garvan to our list of prestigious researchers to adopt the 404pi platform,” said Rick Whitcomb, President and CEO of BiOptix. “This is just the beginning of our relationship with Garvan as we work with them to further their research.”
Source: http://www.bioptix.com/